How Recent Data Impacts Pancreatic Cancer Management

Integrity CE

M. Pishvaian

ASCO® 2024 Insights: "The GIANT Trial (EA2186) - Gem & nab-Paclitaxe…

2024 ASCO® Annual Meeting Insights Hub

E. Dotan

Updates in Perioperative Therapy of Pancreatic Cancer

Horizon CME

P. Philip

Clinical Takeaways in From Recent Key Trials in Pancreatic Cancer

Hani Babiker

Debates in Neoadjuvant Therapy in Resectable Pancreatic Cancer: Why …

Integrity CE

W. Burns

ASCO® 2024 Insights: "Biomarker-Directed Treatment for Pancreatic Ad…

2024 ASCO® Annual Meeting Insights Hub

J. Knox

ASCO® 2024 Insights: "Summary of the PASS-01 Trial - 1L FOLFIRINOX v…

ecancer

J. Knox

ASCO® 2024 Insights: "EXPEL-PANC - A Ph2 Study of BXCL701 + Pembro i…

2024 ASCO® Annual Meeting Insights Hub

B. Weinberg

ESMO GI 2024 Insights: Role of Personalized Medicine in Pancreatic C…

Insights from 2024 ESMO GI Annual Meeting

T. Seufferlein

GI Oncology Year in Review: Precision Medicine Update in Metastatic …

Yale Cancer Center

J. Lacy

GI Oncology Year in Review: Metastatic Pancreatic Cancer - NAPOLI-3 …

Yale Cancer Center

J. Lacy

Perspectives on the Recent FDA Approval of NALIRIFOX in Frontline Me…

UCLA Health

Z. Wainberg

Updates in Nonmetastatic Upper-GI Adenocarcinoma

Integrity CE

J. Hernandez

Precision Medicine in GI Cancers

Fred Hutchinson Cancer Center

D. Zhen

ASCO® 2024 Insights: "Efficacy, Safety, and PD of CM24 With Nivo & C…

2024 ASCO® Annual Meeting Insights Hub

T. Macarulla

ASCO® 2023 Summary: "GI Expert Panel Discussion on Key Trials Includ…

Insights from 2023 ASCO® Annual Meeting

Y. Janjigian, S. Cytryn, S. Maron

Year in Review: Pancreatic Cancers

OncoAlert

M. Lewis

FDA Approval of Liposomal Irinotecan/NALIRIFOX in 1L Metastatic Panc…

Shubham Pant

Selecting Patients Wisely for Neoadjuvant Therapy in Pancreatic and …

ecancer

S. Shrikhande

Optimizing 1L Treatment for Metastatic Pancreatic Cancer: Evaluating…

Angelo Pirozzi